Skip to content

Survey on treatment pattern of advanced hepatocellular carcinoma patients in China (SPHERE-A)

Survey on treatment pattern of advanced hepatocellular carcinoma patients in China (SPHERE-A)

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086982
Enrollment
Unknown
Registered
2024-07-16
Start date
2024-07-31
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Observation group:Physician survey, no intervention involved.

Sponsors

Shanghai Tenth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The criteria of physician who will give input to the questionnaire: • work in tertiary A hospital • =5 years of experience in managing aHCC (BCLC C/ CNLC IIIa+IIIb) patients with the title of chief physician • physicians with =10 aHCC (BCLC C/ CNLC IIIa+IIIb) patients in the past 3 months of practice. • Have prescribed TKIs and IOs in the past 3 months. • Participated aHCC related guideline or consensus in the past 2 years. The criteria of Physician recruiting: • work in secondary A hospital or above • =5 years of experience in managing aHCC (BCLC C/ CNLC IIIa+IIIb) patients with the title of vice chief physician or chief physician • Patient load: physicians with =10 aHCC (BCLC C/ CNLC IIIa+IIIb) patients in the past 6 months of practice. • Have prescribed TKIs and IOs in the past 1 year. • All eligible physicians need to provide informed consent

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Different treatment options distribution for aHCC patients in primary and subsequent treatment separately;Decision making factors for primary and subsequent treatment setting;

Secondary

MeasureTime frame
Systemic treatment regimens for aHCC in China: drugs (different drugs within the same category) and schedule;Decision making factors on drugs for aHCC;

Countries

China

Contacts

Public ContactLi Jun

Shanghai Tenth People’s Hospital

lijundfgd@163.com+86 21 6630 2905

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026